{"filing":{"accession_number":"0001664710-26-000034","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"kros-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000034/kros-20260603.htm"},"events":[{"id":7309,"run_id":6417,"accession_number":"0001664710-26-000034","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Keros Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing reports final voting tallies for three proposals: election of two directors (Proposal 1), ratification of Deloitte \u0026 Touche LLP as auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with specific vote counts for each. This is a quintessential Item 5.07 shareholder_vote_results disclosure.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4145,"accession_number":"0001664710-26-000034","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Keros Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing reports final voting tallies for three proposals: election of two directors (Proposal 1), ratification of Deloitte \u0026 Touche LLP as auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with specific vote counts for each. This is a quintessential Item 5.07 shareholder_vote_results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:31.046282+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4145,"accession_number":"0001664710-26-000034","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Keros Therapeutics' 2026 Annual Meeting of Stockholders held on June 3, 2026. The filing reports final voting tallies for three proposals: election of two directors (Proposal 1), ratification of Deloitte \u0026 Touche LLP as auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with specific vote counts for each. This is a quintessential Item 5.07 shareholder_vote_results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:50:31.046282+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-06-03"}]}